AV-380

BIOLOGICAL2 trials

Sponsors

AVEO Pharmaceuticals, Inc.

Conditions

Cachexia

Phase 1

A Phase 1 Study of AV-380 in Healthy Subjects

CompletedNCT04815551

AVEO Pharmaceuticals, Inc.Cachexia

Start: 2021-02-22End: 2022-01-14Updated: 2023-06-12

A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia

RecruitingNCT05865535

AVEO Pharmaceuticals, Inc.Cachexia

Start: 2023-06-13End: 2026-12-31Target: 30Updated: 2026-01-08

Related Papers

A phase 1b dose escalation study of AV-380 (anti-GDF15 monoclonal antibody) in combination with standard-of-care therapy in cancer patients with cachexia.

Journal of Clinical Oncology2025-05-281 citations

Abstract LB_C02: A phase 1b dose escalation study of AV-380 in combination with standard of care chemotherapy in metastatic cancer patients (pts) with cachexia and elevated GDF-15 levels

Molecular Cancer Therapeutics2023-12-01